Short answer
ARTIVION, INC. (AORT) filed an 8-K current report with the SEC on May 18, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Artivion completed its acquisition of Endospan, an Israeli aortic-device developer.
ARTIVION, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Artivion completed its acquisition of Endospan, an Israeli aortic-device developer
- Endospan’s Nexus™ product expands Artivion’s portfolio for treating aortic instability
- Transaction completion marks transition from deal announcement to integration and commercialization execution
- Exhibit 99.1 contains the acquisition press release and related transaction details
Item 8.01 · Other Events
- Endospan acquisition closed May 18, 2026, adding its NEXUS™ Aortic Arch Stent Graft System to Artivion’s portfolio
- Net cash purchase price approximately $131.3 million after offsetting intercompany loans
- $16.5 million indemnity escrow and $1.0 million adjustment escrow temporarily constrain deployed capital
- Sellers eligible for up to $200.0 million contingent consideration tied to NEXUS™ performance, payable approximately two years after closing
- Investor focus: integration execution, NEXUS™ adoption, and potential future cash obligations beyond the upfront payment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARTIVION, INC. 8-K filings
Get the next AORT 8-K as it lands
Follow AORT for push alerts, or ask the research agent what this filing means.